Stay updated with breaking news from Metastasis Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aging and age-related disorders pose a complex challenge to the biomedical research community. To better understand how senescence is regulated is of high significance to promote healthy aging and treat age-associated disorders.
Due to the development of resistance to chemotherapy and recurring tumors, patients with ovarian cancer often have low survival rates.
Immunotherapies have shown striking clinical benefit in the treatment of many cancers, especially when used in combination with chemotherapy.
Genomic Test Helps Guide Precision Medicine to Estimate Risk of Prostate Cancer Metastasis, Death February 11, 2021 San Francisco, CA (UroToday.com) -- A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers. Researchers studied prostate cancer samples from 352 participants in the NRG/RTOG 9601 clinical trial, which compared radiation therapy alone with radiation therapy combined with hormone ...
(1) BEDMINSTER, N.J., Jan. 15, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with The Wistar Institute, an international leader in biomedical research, to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms. PAD4 is an enzyme that catalyzes conversion of arginine to cit...